Following on from information provided to NICE by the company in January 2019, the appraisal of Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer [ID1413] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 1413

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
22 November 2022 Discontinued. Following on from information provided to NICE by the company in January 2019, the appraisal of Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer [ID1413] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
09 March 2020 The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer [ID1413]. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
25 January 2019 Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps
22 July 2016 In progress. Topic referred

For further information on our processes and methods, please see our CHTE processes and methods manual